

Helsinki 4.6.2002

PCT/SE 02/00848

20-06-2002

ETUOIKEUSTODISTUS  
PRIORITY DOCUMENT

REC'D 16 SEP 2002

WIPO PCT



Hakija  
Applicant

1. Laukkanen, Mikko, Kuopio
2. Ylä-Herttuala, Seppo, Vuorela

Patenttihakemus nro  
Patent application no

20010898

Tekemispäivä  
Filing date

30.04.2001

Kansainvälinen luokka  
International class


C12N

Keksinnön nimitys  
Title of invention

"Extracellular superoxide dismutase (EC-SOD) gene therapy for inhibiting restenosis"  
(Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosin ehkäisemiseksi)

Täten todistetaan, että oheiset asiakirjat ovat tarkkoja jäljennöksiä patentti- ja rekisterihallitukselle alkuaan annetuista selityksestä, patenttivaatimuksista, tiivistelmästä ja piirustuksista.

This is to certify that the annexed documents are true copies of the description, claims, abstract and drawings originally filed with the Finnish Patent Office

  
Pirjo Kalla  
Tutkimussihteeri

PRIORITY  
DOCUMENT

Maksu 50 €  
Fee 50 EUR

Maksu perustuu kauppa- ja teollisuusministeriön antamaan asetukseen 1027/2001 Patentti- ja rekisterihallituksen maksullisista suoritteista muutoksineen.

The fee is based on the Decree with amendments of the Ministry of Trade and Industry No. 1027/2001 concerning the chargeable services of the National Board of Patents and Registration of Finland.

Osoite: Arkadiankatu 6 A  
P.O.Box 1160

Puhelin: 09 6939 500  
Telephone: + 358 9 6939 500

Telefax: 09 6939 5328  
Telefax: + 358 9 6939 5328

CERTIFIED COPY OF  
PRIORITY DOCUMENT

# Extracellular superoxide dismutase (EC-SOD) gene therapy for inhibiting restenosis

## FIELD OF THE INVENTION

- 5 The invention relates to the use of adenovirus-mediated extracellular superoxide dismutase (EC-SOD) gene/cDNA transfer to aorta and other blood vessels on neointima formation.

## BACKGROUND OF THE INVENTION

- 10 Conventional treatment of atherosclerotic vascular diseases has improved significantly due to the use of drugs, angioplasty, bypass grafting, endarterectomy, and stent implantation. However, restenosis is still an important complication of the invasive treatment. By restenosis it is meant the reoccurrence of stenosis, which is a condition result of disease in which the aorta and especially its orifice is abnormally narrow, in a blood vessel after it has been treated (as by angioplasty) with apparent  
15 success. It occurs in 20-30% of patients and is due to proliferation and migration of smooth muscle cells and myofibroblasts, which leads to formation of neointima. By neointima it is meant a new or thickened layer of arterial inner layer of blood vessel formed by migration and proliferation of cells from the media.

- 20 Restenosis is a vascular response to percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass grafting (CABG) and coronary stenting causing intimal hyperplasia formation in 20-30% of patients<sup>1; 2</sup>; 2. Balloon angioplasty frequently causes intimal tearing, endothelial cell damage and exposure of subendothelial tissue to blood components<sup>3</sup> leading to increased oxidative stress, superoxide anion (O<sub>2</sub><sup>-</sup>) production<sup>4; 5</sup>; 5, {Laurindo, da Luz, et al. 1991 ID: LAURINDO1991} and decreased vascular superoxide dismutase concentration<sup>4</sup>.  
25

- 30 Treatment of restenosis has so far been largely unsuccessful despite of numerous efforts. Restenosis is most effectively inhibited by inducing endothelial cell growth with vascular endothelial growth factors (VEGF) and nitric oxide (NO) related genes<sup>6</sup>. VEGF-A or VEGF-C induce endothelial repair but do not decrease oxidative stress and infiltration of macrophages. Macrophages are known to secrete many cytokines and growth factors which induce SMC proliferation and participate neointima formation<sup>7; 8</sup>.

In the US patents 5,788,961 and 5,472,691 the EC-SOD protein has been studied for its therapeutic effect in treating ischemia and inflammatory diseases and other conditions of the body associated with the presence or formation of superoxide radicals. However, gene therapy by the EC-SOD gene/cDNA has not been  
5 evaluated.

## SUMMARY OF THE INVENTION

The object of the invention is to analyse the effects of adenovirus-mediated extracellular superoxide dismutase (EC-SOD) gene/cDNA transfer to aorta and other blood vessels on neointima formation.

10 Secreted EC-SOD as an antioxidative<sup>9</sup> enzyme may offer a potential tool for vascular gene/cDNA therapy since it is capable of binding to heparan sulphate proteoglycans on the surface of vascular endothelial cells<sup>10</sup>. In previous studies EC-SOD has been shown to reduce O<sub>2</sub><sup>-</sup> mediated macromolecular and cellular  
15 damages in vitro and in vivo suggesting that EC-SOD gene/cDNA therapy may be used to correct tissue damages caused by free radicals<sup>9; 11; 11; 12; 12; 13; 13</sup>. In addition to dismutase activity EC-SOD, and other SODs, have been hypothesised to have other enzymatic properties, which would enlarge the biological range of the SOD family<sup>14</sup>.

About 50% of the total SOD activity in human aorta is EC-SOD<sup>15; 16; 16</sup>. In most  
20 of the other tissues EC-SOD represents only a minor part of the total SOD activity<sup>17</sup>, which suggests that EC-SOD has a significant physiological role in redox balance of vascular walls.

The applicant has shown that adenovirus mediated EC-SOD gene/cDNA transfer resulted in a significant ( $p < 0.001$ ) inhibition of neointima formation in rabbit aortas  
25 after balloon denudation. It was found that EC-SOD inhibited significantly neointima formation. The therapeutical effect was affecting the whole abdominal aorta studied suggesting a systemic effect. According to the present application EC-SOD is an efficient therapeutical molecule to prevent restenosis.

## BRIEF DESCRIPTION OF THE FIGURES

30 The invention will now be described in detail with reference to the figure.

Figure 1. Histological analysis of serial sections from abdominal aorta two weeks after gene/cDNA transfer. Panels A, C, E, G, I, K, and M represent EC-SOD group

and panels B, D, F, H, J, L, and N represent LacZ group. Arrows indicate the location of internal elastic lamina. A. and B. H-E staining; C and D internal elastic lamina determination; E and F endothelium staining (CD-31); G and H BrdU staining; I and J macrophage staining (Ram 11); K and L NADPH-oxidase staining (p67phox); M and N SMC staining (HHF-35). Intima/media area ratio, cell proliferation, and accumulation of macrophages were significantly decreased in EC-SOD group whereas endothelium recovery was significantly increased in EC-SOD group as compared to LacZ controls. Measurement of internal elastic lamina showed similar damage in both groups.

## 10 DETAILED DESCRIPTION OF THE INVENTION

Oxidative stress is associated with several diseases and tissue damage either as a cause or a consequence of a disease. Increased production of reactive oxygen species is detected in vascular disorders, such as ischemia and atherogenesis leading to oxidative stress. Oxidative stress is attenuated by antioxidative agents and several types of antioxidative enzymes.

Extracellular superoxide dismutase (EC-SOD) is a secreted antioxidative enzyme; which is widely expressed throughout the body and is the major SOD isoenzyme in plasma. Vessel wall, lung, kidney, thyroid gland, and epidymis are shown to be the primary expression sites for the EC-SOD. About 50% of total SOD amount in human aorta is EC-SOD. In most other tissues EC-SOD represents only a minor part of the total SOD activity, which suggests that EC-SOD has a significant physiological role in redox balance of vascular wall.

In the present application rabbit extracellular superoxide dismutase (EC-SOD), which is one of the three superoxide dismutase isoforms known in mammals, is used to study the adequacy of EC-SOD for gene therapy. The rabbit cDNA and gene were cloned from phage libraries for sequence, mutation, and expression analysis<sup>9</sup>; 18. The expression and functionality of EC-SOD was studied in vitro and in vivo using nonviral and adenovirus mediated gene/cDNA transfer methods. Therapeutical effects were tested in mouse and rabbit models<sup>11</sup>; 19.

The antioxidative role and therapeutical properties were shown in vitro and in vivo. EC-SOD isolated from culture medium after adenovirus mediated gene/cDNA transfer reduced endothelial cell-mediated oxidative modification of low density lipoprotein (LDL) suggesting the functionality of the cloned cDNA<sup>9</sup>. The therapeutical properties were tested in mice<sup>11</sup>; 19 and rabbits after adenovirus

mediated gene/cDNA transfer. In mice EC-SOD efficiently inhibited paracetamol-induced liver damage and in New Zealand White (NZW) rabbits EC-SOD efficiently attenuated neointima formation after balloon denudation, indicating a broad therapeutic window and functionality of EC-SOD in different radical based dysfunctions. Since oxygen free radicals are involved in the formation of tissue injury, EC-SOD could be useful for therapeutical applications in several diseases.

There are only a few gene/cDNA therapy studies with EC-SOD<sup>11</sup>; <sup>11-13</sup>; <sup>13</sup> even though EC-SOD is potentially more suitable for vascular mediated gene/cDNA transfer than other SODs. It is a secreted enzyme<sup>20</sup> capable to bind reversibly to heparan sulphate on the cell membranes<sup>10</sup>, and has a remarkable long (20 h) half life in circulation<sup>21</sup>. Recent studies with EC-SOD transgenic animals have shown that EC-SOD can significantly reduce tissue damage caused by oxygen derived free radicals<sup>22</sup>; <sup>23</sup>; <sup>23</sup>; <sup>24</sup>; <sup>24</sup>; <sup>25</sup>; <sup>25</sup>; <sup>26</sup>; <sup>26</sup>; <sup>27</sup>; <sup>27</sup>.

In the present application it is shown that adenovirus mediated EC-SOD gene/cDNA transfer resulted in a significant ( $p < 0.001$ ) inhibition of neointima formation in ballooned rabbit aortas. EC-SOD transduced rabbits had significantly increased endothelium recovery and significantly reduced macrophage accumulation into vessel wall. Both of these alone have been reported to reduce neointima growth in animal models<sup>8</sup>; <sup>28</sup>. The reduced infiltration of macrophages suggests anti-inflammatory role for EC-SOD in addition to antioxidative role which have been shown in previous studies<sup>9</sup>. Results from BrdU labelling showed low proliferation in EC-SOD transduced vessels.

In the present application it is analyzed the effects of adenovirus-mediated extracellular superoxide dismutase (EC-SOD) gene/cDNA transfer on neointima formation after endothelial denudation in rabbits. Two weeks after the gene/cDNA transfers ( $3 \times 10^9$  pfu/kg AdEC-SOD or AdLacZ) aortas were isolated and neointima formation was studied using histological and morphometric analysis. Intima/media ratio in EC-SOD transduced rabbits was significantly ( $p < 0.001$ ) decreased in the whole abdominal aorta as compared to LacZ transduced control rabbit abdominal aortas suggesting a systemic effect. The recovery of endothelial cells was significantly ( $p < 0.001$ ) increased whereas the number of macrophages ( $p < 0.001$ ), and BrdU positive cells were significantly reduced in EC-SOD rabbit aortas (intima  $p < 0.01$  and media  $p < 0.05$ ). The results suggest that delivery of EC-SOD adenoviruses is a useful tool for the treatment of postangioplasty restenosis and vessel wall thickening after vascular manipulations.

The invention will be further described with reference to the following non-limiting examples.

### Example 1

#### Animal experiments

20 New Zealand White rabbits (EC-SOD n=10 and LacZ n=10) were kept on 0.25% cholesterol diet for two weeks before balloon denudation. In the denudation the whole aorta beginning from the tip of the arch was denuded using 3.0 F arterial embolectomy catheter (Sorin Biomedical, Irvine, CA). The catheter was introduced via the right iliac artery up to the aortic arch and inflated, and the aorta was denuded twice<sup>29</sup>.

Three days after denudation adenovirus mediated EC-SOD or LacZ control gene/cDNA transfer ( $2 \times 10^9$  pfu) was performed using systemic virus injection or Dispatch catheter (Boston Scientific Corp., Maple Grove, MA) which allows continuous blood flow during transduction<sup>30</sup>. Using fluoroscopic control, the catheter was positioned caudal to the left renal artery via 4 F percutaneous introducer sheath (Arrow International, Reading, PA) in the right carotid artery inflated to 6 ATM with the mixture of contrast media and saline. The gene transfer was performed for 10 minutes (0.2 ml/min. total volume being 2 ml). Two weeks after gene/cDNA transfer adenovirus transduced aortas were isolated. Serum samples were collected before gene/cDNA transfer, three days after the gene/cDNA transfer, seven days after the gene/cDNA transfer and at the end of the experiment. Tissue samples were collected to determine the distribution of adenovirus.

### Example 2

#### Adenovirus production

The EC-SOD cDNA was cloned into BamHI site of eukaryotic expression plasmid<sup>31</sup>, which contains elongation factor 1 $\alpha$  (EF1 $\alpha$ ) promoter. The resulting expression cassette contains EF1 $\alpha$  promoter followed by rabbit EC-SOD cDNA followed by G-CSF polyadenylation signal. The EC-SOD expression cassette was cloned into an adenovirus vector (AdBgIII) by digesting eukaryotic expression vector with PvuII restriction enzyme. The vector AdBgIII was digested with BgIII and the overhangs were filled. EC-SOD expression cassette was subcloned into AdBgIII with blunt-end ligation<sup>9</sup>. LacZ adenovirus was used as a control<sup>32</sup>. Adenoviruses were produced in 293 cells and analysed to be free of microbiological

contaminants, mycoplasma, endotoxin and replication-competent viruses<sup>9</sup>. The adenovirus production was done using standard recombination techniques<sup>33</sup>.

### Example 3

#### EC-SOD activity analysis

- 5 The efficiency of adenovirus gene transfer was determined by measuring total SOD activity from the plasma as described<sup>34</sup>. Briefly, 25-50  $\mu$ l sample was added to 3 ml 50mM AMP/HCl pH 9.5/0.2 mM DTPA buffer and blanked before addition of kaliumperoxide (KO<sub>2</sub>) substrate in 50 mM NaOH/0.5 mM DTPA (Sigma). The reaction was followed five minutes at wavelength 250 nm (Lambda Bio, Perkin  
10 Elmer). The activity was calculated by determining the half-times of O<sub>2</sub><sup>-</sup> decay at A<sub>250</sub>. One unit in the assay is defined as the activity that brings about a decay in O<sub>2</sub><sup>-</sup> concentration at a rate of 0.1s<sup>-1</sup> in 3ml buffer and corresponds to 8.6 ng of human EC-SOD as quantified by ELISA<sup>34</sup>.

### Example 4

#### 15 Histological analysis

- Four hours before sacrifice, animals were injected with 50 mg iv. of bromodeoxyuridine (BrdU) (Sigma) dissolved in 40% ethanol. Transduced segment of the aorta was removed, flushed gently with saline and divided into four equal parts used for histological paraffin sections, cryo sections, BrdU sections and one  
20 piece stored at -70 C°. Paraffin sections were immersion-fixed in 4% paraformaldehyde/15% sucrose (pH 7.4) for four hours, rinsed overnight in 15% sucrose (pH 7.4) and embedded in paraffin. Cryo sections were fixed in 4% paraformaldehyde/15% sucrose (pH 7.4) for 10 minutes, rinsed in PBS, embedded in O.C.T. compound (Miles Scientific, Elkhart) and stored at -70 C. BrdU sections were fixed  
25 in 70% ethanol for five hours and embedded in paraffin. Gene transfer efficiency was determined by x-gal staining in x-gal staining solution for 6 hours at +37 C<sup>35</sup>. Neointima formation was measured after hematoxylin/eosin staining using Image-pro plus software with Olympus AX70 microscope (Olympus Optical). Determination of BrdU positive cells was done using immunohistochemistry  
30 (Bromodeoxyuridine, clone Bu20a, dilution 1:200, DAKO) according to manufacturers instructions.

Following antibodies were used to study the effect of gene transfer: CD34 (endothelium, dilution 1:50, DAKO), RAM 11 (macrophages, dilution 1:200,

- DAKO), HHF35 (SMC, dilution 1:50, DAKO), p67phox (NADPH oxidase, dilution 1:100, Transduction Laboratories) eNOS (dilution 1:25, Transduction Laboratories), iNOS (dilution 1:50, Transduction Laboratories), VEGF-A (dilution 1:100, Santa Cruz), VEGF-C (dilution 1:100, Santa Cruz), NF-kappaB (dilution 1:50, Transduction Laboratories), BrdU positive cells (Bromodeoxyuridine, clone Bu20a, dilution 1:200, DAKO). Avidin-biotin-horseradish peroxidase system was used for signal detection (Vector Elite Kit).

## Example 5

### 5.1 Statistical analysis

- 10 Statistical analysis was done using ANOVA and modified t-test.

Gene transfer site and adjacent portions of abdominal aorta were analysed immunohistologically from a total of 20 animals (10 EC-SOD and 10 LacZ control rabbits) to study the effect of adenoviral EC-SOD gene transfer on restenosis.

### 5.2 Histological analysis

- 15 To determine the effect of EC-SOD gene/cDNA transfer on neointima formation the intima-media area ratio from aortic samples was measured. Histological analysis showed significantly ( $p < 0.001$ ) reduced neointimal hyperplasia in EC-SOD group as compared to LacZ controls in the region from renal artery to aortic bifurcation suggesting systemic effect for prevention of restenosis (Fig. 1 a and b)). The mean  
20 ( $\pm$ SD) neointima/media area ratio in EC-SOD transduced rabbits was  $0.091 \pm 0.054$  and in LacZ rabbits  $0.326 \pm 0.098$  indicating significant ( $p < 0.001$ ) reduction in restenosis.

- Since the neointima formation in balloon denuded rabbit model is dependent on the endothelial balloon damage the length of internal elastic lamina (IEL) was  
25 determined from each aortic sample (Fig. 1 c and d). The measurement showed 4% damage to IEL in both EC-SOD and in LacZ control groups indicating similar damage to endothelium after denudation. Aortic sections stained with CD31 for endothelial cells showed 86% ( $p < 0.001$ ) recovery of vessel endothelium after denudation in EC-SOD group whereas in LacZ control group the endothelial  
30 recovery was only 21% (Fig. 1 e and f).

BrdU staining (Fig. 1 g and h) showed 10-fold higher proliferation ( $p < 0.01$ ) in neointima and 2-fold higher ( $p < 0.05$ ) proliferation in media of LacZ control group



as compared to EC-SOD group. Activated macrophages express several cytokines and growth factors, such as interleukin-1, platelet derived growth factor, and insulin-like growth factor 136. RAM 11 staining for macrophages (Fig. 1 i and j) showed a 10-fold decreased ( $p < 0.001$ ) macrophage infiltration into neointima in EC-SOD group. NADPH oxidase, which is reported to be up-regulated in restenotic rabbit aortas<sup>5</sup>, was stained at the similar regions as macrophages (Fig. 1 k and l). Intimal thickening is mostly caused by migration and proliferation of SMCs<sup>37</sup> (Fig. 3 m and n) but also macrophages are present in high abundance<sup>38</sup>.

The results show that EC-SOD gene/cDNA transfer is a useful tool for the treatment of postangioplasty restenosis and vessel wall thickening after vascular manipulations.

The invention has been illustrated by examples and embodiments, but it may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention and all such modifications are intended to be included within the scope of the enclosed claims.

## Reference List

1. Bittl JA: Advances in coronary angioplasty. *N.Engl.J.Med.* 1996;335:1290-1302
2. Narins CR, Holmes DR, Topol EJ: A call for provisional stenting: the balloon is back! *Circulation* 1998;97:1298-1305
3. Janero DR, Ewing JF: Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential. *Free Radic.Biol Med.* 2000;29:1199-1221
4. Laurindo FR, da Luz PL, Uint L, Rocha TF, Jaeger RG, Lopes EA: Evidence for superoxide radical-dependent coronary vasospasm after angioplasty in intact dogs. *Circulation* 1991;83:1705-1715
5. West N, Guzik T, Black E, Channon K: Enhanced superoxide production in experimental venous bypass graft intimal hyperplasia: role of NAD(P)H oxidase. *Arterioscler.Thromb.Vasc.Biol* 2001;21:189-194
6. Yla-Herttuala S, Martin JF: Cardiovascular gene therapy. *Lancet*;355(9199.):213-22 1-15-0;355:213-222
7. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. *Nature* 1993;362:801-809
8. Ross R: Atherosclerosis—an inflammatory disease. *N.Engl.J Med.* 1999;340:115-126
9. Laukkanen MO, Lehtolainen P, Turunen P, Aittomaki S, Oikari P, Marklund SL, Yla-Herttuala S: Rabbit extracellular superoxide dismutase: expression and effect on LDL oxidation. *Gene* 2000;254:173-179
10. Karlsson K, Marklund SL: Heparin-induced release of extracellular superoxide dismutase to human blood plasma. *Biochem.J.* 1987;242:55-59
11. Laukkanen, M. O., Leppanen, P., Turunen, P, Tuomisto, T, Naarala, J, and Yla-Herttuala, S. EC-SOD gene therapy reduces paracetamol-induced liver damage in mice. *Journal of Gene Medicine* 3(3). 2001.

12. Li Q, Bolli R, Qiu Y, Tang XL, Murphree SS, French BA: Gene therapy with extracellular superoxide dismutase attenuates myocardial stunning in conscious rabbits. *Circulation* 1998;98:1438-1448
13. Li Q, Bolli R, Qiu Y, Tang XL, Guo Y, French BA: Gene therapy with extracellular superoxide dismutase protects conscious rabbits against myocardial infarction. *Circulation* 2001;103:1893-1898
14. Petyaev IM: New catalytic properties of superoxide dismutase: Biological and medical implications, in *Superoxide dismutases: Recent advances and clinical applications*. Paris-Tokyo, Editions Mel Paris, 1999, pp 40-44
15. Luoma JS, Strålin P, Marklund SL, Hiltunen TP, Särkioja T, Ylä-Herttuala S: Expression of extracellular SOD and iNOS in macrophages and smooth muscle cells in human and rabbit atherosclerotic lesions - Colocalization with epitopes characteristic of oxidized LDL and peroxynitrite-modified proteins. *Arterioscler Thromb Vasc Biol* 1998;18:157-167
16. Stralin P, Karlsson K, Johansson BO, Marklund SL: The interstitium of the human arterial wall contains very large amounts of extracellular superoxide dismutase. *Arterioscler.Thromb.Vasc.Biol.* 1995;15:2032-2036
17. Marklund SL: Extracellular superoxide dismutase and other superoxide dismutase isoenzymes in tissues from nine mammalian species. *Biochem.J.* 1984;222:649-655
18. Laukkanen MO, Mannermaa S, Hiltunen MO, Aittomaki S, Airenne K, Janne J, Yla-Herttuala S: Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. *Arterioscler.Thromb.Vasc.Biol* 1999;19:2171-2178
19. Laukkanen, M., Leppanen, P., Turunen, P, Porkkala-Sarataho, E., Salonen, J. T., and Yla-Herttuala, S. Gene transfer of extracellular superoxide dismutase to atherosclerotic mice. *Antioxidant and Redox Signalling* in print. 2001.
20. Marklund SL: Human copper-containing superoxide dismutase of high molecular weight. *Proc.Natl.Acad.Sci.U.S.A.* 1982;79:7634-7638
21. Karlsson K, Sandström J, Edlund A, Edlund T, Marklund SL: Pharmacokinetics of extracellular-superoxide dismutase in the vascular system. *Free Radic.Biol.Med.* 1993;14:185-190

22. Oury TD, Piantadosi CA, Crapo JD: Cold-induced brain edema in mice. Involvement of extracellular superoxide dismutase and nitric oxide. *J.Biol.Chem.* 1993;268:15394-15398
23. Chen EP, Bittner HB, Davis RD, Folz RJ, Van Trigt P: Extracellular superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts. *Circulation* 1996;94:II412-II417
24. Folz RJ, Abushamaa AM, Suliman HB: Extracellular superoxide dismutase in the airways of transgenic mice reduces inflammation and attenuates lung toxicity following hyperoxia. *J.Clin.Invest.* 1999;103:1055-1066
25. Sheng H, Bart RD, Oury TD, Pearlstein RD, Crapo JD, Warner DS: Mice overexpressing extracellular superoxide dismutase have increased resistance to focal cerebral ischemia. *Neuroscience* 1999;88:185-191
26. Sheng H, Kudo M, Mackensen GB, Pearlstein RD, Crapo JD, Warner DS: Mice overexpressing extracellular superoxide dismutase have increased resistance to global cerebral ischemia. *Exp.Neurol.* 2000;163:392-398
27. Suliman HB, Ryan LK, Bishop L, Folz RJ: Prevention of influenza-induced lung injury in mice overexpressing extracellular superoxide dismutase. *Am.J Physiol.Lung Cell Mol.Physiol.* 2001;280:L69-L78
28. Asahara T, Chen D, Tsurumi Y, Kearney M, Rossow S, Passeri J, Symes JF, Isner JM: Accelerated restitution of endothelial integrity and endothelium-dependent function after phVEGF165 gene transfer. *Circulation* 1996;94:3291-3302
29. Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, Laukkanen J, Niemi M, Kossila M, Hakkinen TP, Kivela A, Enholm B, Mansukoski H, Turunen AM, Alitalo K, Yla-Herttuala S: Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. *Circulation* 2000;102:2262-2268
30. Laitinen M, Hartikainen J, Hiltunen MO, Eranen J, Kiviniemi M, Narvanen O, Makinen K, Manninen H, Syvanne M, Martin JF, Laakso M, Yla-Herttuala S: Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty. *Hum.Gene Ther.* 2000;11:263-270

31. Mizushima S, Nagata S: pEF-BOS, a powerful mammalian expression vector. *Nucleic.Acids.Res.* 1990;18:5322
32. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J, Lehtolainen P, Viita H, Agrawal R, Miyanochara A, Friedmann T, Risau W, Martin JF, Soma M, Ylä-Herttuala S: Gene transfer into the carotid artery using an adventitial collar: comparison of the effectiveness of the plasmid- liposome complexes, retroviruses, pseudotyped retroviruses, and adenoviruses. *Hum. Gene Ther.* 1997;8:1645-1650
33. Kozarsky KF, Wilson JM: Gene therapy: adenovirus vectors. *Curr.Opin.Genet.Dev.* 1993;3:499-503
34. Marklund S: Spectrophotometric study of spontaneous disproportionation of superoxide anion radical and sensitive direct assay for superoxide dismutase. *J.Biol.Chem.* 1976;251:7504-7507
35. Ylä-Herttuala S, Luoma J, Viita H, Hiltunen T, Sisto T, Nikkari T: Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. *J.Clin.Invest.* 1995;95:2692-2698
36. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK: A cascade model for restenosis. A special case of atherosclerosis progression. *Circulation* 1992;86:III47-III52
37. Liu MW, Roubin GS, King SB: Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. *Circulation* 1989;79:1374-1387
38. Waller BF, Pinkerton CA, Orr CM, Slack JD, VanTassel JW, Peters T: Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty. *Circulation* 1991;83:I28-I41

## Claims

1. Extracellular superoxide dismutase (EC-SOD) gene/cDNA for the treatment of restenosis.
2. Extracellular superoxide dismutase (EC-SOD) gene/cDNA for the treatment of blood vessel thickening.
3. Extracellular superoxide dismutase (EC-SOD) gene/cDNA for increasing endothelial cell growth.
4. Extracellular superoxide dismutase (EC-SOD) gene/cDNA for decreasing macrophage accumulation.
5. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for the treatment of restenosis.
6. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for the treatment of blood vessel thickening.
7. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for increasing endothelial cell growth.
8. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for decreasing macrophage accumulation.
9. The use according to claims 5 to 8 wherein adenovirus or plasmid containing EC-SOD is used.
10. The use according to claims 5 to 9 wherein rabbit EC-SOD cDNA is used.
11. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for manufacturing of a medicament for treating of restenosis.
12. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for manufacturing of a medicament for treating of blood vessel thickening.
13. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for manufacturing of a medicament for increasing endothelial cell growth.
14. Use of extracellular superoxide dismutase (EC-SOD) gene/cDNA for manufacturing of a medicament for decreasing macrophage accumulation.

15. Use of one of the claims 11 to 14 wherein the medicament is administered by local or systemic delivery.

(57) Abstract

The invention relates to the use of adenovirus-mediated extracellular superoxide dismutase (EC-SOD) gene/cDNA transfer to aorta and other blood vessels on neointima formation.






Fig. 1